Sumary of Potential biomarkers of coagulopathy and disease severity in COVID-19:
- Not only do patients display impaired fibrinolysis, but also platelet aggregation, inflammation, and microthrombi.
- Understanding this pathology could help healthcare workers treat these symptoms, often associated with low survival levels in severe COVID-19 patients.
- Study: Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients.
- To further explore this phenomenon, scientists have investigated the presence of specific biomarkers in hospitalized COVID-19 patients.
- A preprint version of the study is available on the medRxiv* server while the article undergoes peer review.
- The study The study included 63 patients showing positive PCR test results for COVID-19 and 43 healthy/non-infected individuals as controls.
- Forty-seven of the infected group had progressed to severe COVID-19, requiring admission to the ICU and showing symptoms such as shock, respiratory distress, and multiorgan dysfunction.
- The remaining patients were hospitalized, but not severe, although one did require mechanical ventilation.